Associação Brasileira de Hematologia, Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. Review article: Cell therapy in solid tumors

The use of immunotherapy in cancer treatment over the past decade has resulted in significant advances and improvements in cancer patients survival with the use of checkpoint inhibitors. Nevertheless, only a fraction of solid tumors responds to this immunotherapy modality. Another modality of immuno...

Full description

Saved in:
Bibliographic Details
Published in:Hematology, Transfusion and Cell Therapy Vol. 43; no. Suppl 2; pp. S78 - S83
Main Authors: Nardo, Mirella, Motta, Tatiane C., Colli, Leandro M., Avanzi, Mauro P.
Format: Journal Article
Language:English
Published: Elsevier España, S.L.U 01.11.2021
Sociedade Brasileira de Hematologia e Hemoterapia
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH)
Elsevier
Subjects:
ISSN:2531-1379, 2531-1387, 2531-1387
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The use of immunotherapy in cancer treatment over the past decade has resulted in significant advances and improvements in cancer patients survival with the use of checkpoint inhibitors. Nevertheless, only a fraction of solid tumors responds to this immunotherapy modality. Another modality of immunotherapy consists of employing cell-based therapy as an adoptive therapeutic modality. That involves distinct modalities of cellular therapies such as CAR T cells (chimeric antigen receptor T cell), TILs (tumor-infiltrating lymphocytes), and TCR T cells. Those treatments have proven effective in hematologic tumors and could have an impact in tumors that do not respond to checkpoint inhibitors. This review aims to outline the rationale, operation, clinical applicability, and results of adoptive cell therapy for patients with solid tumors.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:2531-1379
2531-1387
2531-1387
DOI:10.1016/j.htct.2021.09.011